NCT06651970 2026-04-15
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
Clinical Trials
11 trialsNCT06564038 2026-04-13
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT03804372 2025-02-27
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT00788684 2025-02-20
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Phase 1 Completed
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03582098 2019-04-12
RETRO-idel
Gilead Sciences
Completed
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT01400685 2018-01-25
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Massachusetts General Hospital
Phase 1 Completed
NCT00201721 2017-02-08
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01744626 2016-04-19
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene Corporation
Phase 1 Completed
NCT00558181 2010-02-23
LT-CLL-001
Vilnius University
Phase 2 Completed